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Abstract: Background: In neonatal chylothorax, thoracic lymphatic drainage is ineffective. The resultant 
effusions often require drainage, leading to a loss of immune components. Affected infants can be 
managed with formula or defatted human milk feedings low in long chain triglycerides to decrease lymph 
production. We hypothesized that there is no significant difference in the immunological profile or 
antibacterial effect of full fat and defatted human milk. Methods: Milk from lactating mothers was divided 
into one aliquot that was defatted via centrifugation with the full fat aliquot as control. Macronutrient 
content was analyzed with mid-infrared spectroscopy. Flow cytometry was used to measure immune cell 
populations. Lactoferrin, lysozyme, IgA and IgG values were determined using ELISA. The antibacterial 
properties were determined by inoculating paired full fat and defatted milk samples with Escherichia coli 
or Streptococcus pneumoniae bacteria and performing colony counts. Results: Compared to full fat milk, 
defatted milk demonstrated decreased total energy and fat and increased carbohydrate concentrations. 
Defatted milk demonstrated a significant decrease in all immune cell populations. There was no 
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growth inhibition of Escherichia coli and Streptococcus pneumoniae. Conclusions: Unexpectedly, defatted 
human milk contained significantly less leukocytes than full fat milk. IgA, IgG, lysozyme and lactoferrin 
concentrations were preserved. The ability of defatted milk to inhibit bacterial growth was unaffected, 
suggesting that the antibacterial benefits of human milk remain after the defatting process. Further 
investigation regarding the clinical effect of leukocyte loss in defatted milk is warranted. 
 
Clinical Relevancy Statement: Full fat human milk (FFHM) provides many benefits for infants, including 
improved neurodevelopment and decreased infection risk. The current standard of care for infants with 
chylothorax is feeding with a formula that is low in long chain triglycerides. Defatted human milk (DFHM) 
is an alternative for these infants but is labor intensive to prepare and with unclear immunologic 
ramifications. This study demonstrates that FFHM and DFHM contain equivalent immunologic properties, 
which supports the use of DFHM in infants with chylothorax.   
 
Introduction: 
Neonatal chylothorax is a condition in which thoracic lymphatic drainage is ineffective, resulting in 
chylous pleural effusions. This can be congenital, as in lymphangiectasia, Trisomy 21 or Turner 
Syndrome, or acquired through surgical injury or trauma.1 These effusions can compromise 
cardiorespiratory function, but drainage of effusions results in a loss of immune components and can lead 
to a secondary immunodeficiency. 2,3 Symptomatic chylothorax is initially managed by fasting, parenteral 
nutrition and drainage of the effusions with a thoracostomy tube.1,4 This is followed by formula feedings 
that are low in long chain triglycerides (LCTs), as this decreases lymph production. An alternative feeding 
option is defatted human milk (DFHM), which is also low in LCTs. Studies have shown that feedings with 
DFHM are just as effective for chylothorax resolution as feedings with low LCT formula. 5-7 However, 
infants treated with DFHM have demonstrated reduced growth compared to those on low LCT formula in 
some studies. 5-7 This discordance can be addressed by close monitoring of infant growth and 
customization of DFHM fortification with low LCT formula supplementation. 5-10  
 
Full fat human milk (FFHM) has numerous benefits for the term and preterm infant and is the standard of 
care for infant nutrition.11,12 These benefits include improved neurodevelopmental outcomes, decreased 
infection risk during the neonatal and infant periods, and decreased childhood obesity compared to 
formula fed infants.11,12 FFHM contains multiple immunologically important compounds, including 
maternal immunoglobulins (sIgA, sIgG), maternal immune cells (macrophages, neutrophils, lymphocytes) 
and anti-microbial compounds including free fatty acids, lactoferrin and lysozyme.13-15 These factors 
actively protect the breastfed infant from infection while simultaneously guiding neonatal and infant 
immune development.13 Exclusively formula fed infants do not receive these unique, individualized 
immunologic benefits. FFHM, which is rich in LCTs, is traditionally withheld in infants with chylothorax 
due to concerns that it may worsen the effusions. Because of the known benefits and immune protective 
properties associated with FFHM, some centers are using DFHM as the base nutrition to support infants 
with chylothorax rather than low LCT formula.  Various methods of human milk fat removal have been 
devised in order to remove LCTs.8,9 The amount of fat in DFHM typically ranges from <0.5g fat/dl to 0.9 g 
fat/dl depending on the study and method of measurement.8,9 While triglyceride content has been 
reported as the main outcome measure when comparing defatting methods, changes in immunological 
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proteins, including lactadhedrin and immunoglobulins, are located within milk fat globules, so it is 
plausible that immune related factors could be affected by the defatting process.16,17 However, we 
hypothesized that there would be no significant difference in the immunological profile or antibacterial 
effect of full fat and defatted human milk and sought to fill this gap in the literature.  
 
In this study, we measured macronutrient content, immune cell populations, antimicrobial proteins and 
bacterial growth inhibition in human milk before and after the defatting process. The DFHM samples 
contained less fat and total energy compared to the FFHM samples, while the remaining macronutrients 
were not significantly changed. The DFHM samples contained equivalent lactoferrin, lysozyme, sIgA and 
sIgG compared to the FFHM samples, but had decreased immune cell populations, including T cells, B 
cells, monocytes and neutrophils. Despite this, DFHM demonstrated equivalent growth inhibition of the 
bacteria Escherichia coli (E. coli) and Streptococcus pneumoniae (S. pneumoniae). 
 
Methodology: 
The University of Michigan Institutional Review Board approved this research protocol. Term (37-42 
weeks’ gestation) and preterm (<37 weeks’ gestation) infants admitted to the C.S. Mott Children’s 
Hospital were screened to determine eligibility. Exclusion criteria included mothers <18 years old and 
mothers who were not primarily English speaking. Lactating mothers were offered enrollment into the 
study and written informed consent was obtained. Mothers provided a 30 mL morning expression of 
FFHM from one breast at least 2 hours after the most recent feeding.  To ensure that near mature milk 
was obtained rather than colostrum, samples were collected between 10-60 days of lactation for term 
infants and between 10-28 days of lactation for preterm infants. 18,19 Samples were collected, de-
identified and assigned a study number. Sample sizes for individual experiments are detailed in the 
accompanying graphs.  
 
Samples were stored at 4oC and were processed within 4 days of expression, which is the recommended 
limit of storage time for fresh breast milk by the Academy of Breastfeeding Medicine.20 Each maternal 
sample was divided into two aliquots for evaluation and comparison. One 10 mL aliquot remained whole 
for analysis (FFHM). The remaining 20 mL was processed in a centrifuge (2oC, 3000 RPM for 15 minutes) 
to separate the DFHM from the cream layer using the Hermle Z446K centrifuge. The DFHM was poured 
off to bypass the cream layer disk into a new bottle for testing. Creamatocrit testing on a Medela 
Crematocrit Plus was performed per manufacturer instructions to ensure the sample was adequately 
defatted with a value of <3% cream. FFHM and DFHM samples were either used fresh or were frozen at -
20oC. 
Macronutrients:  
Stored frozen FFHM and DFHM samples (5 mL) were thawed on ice, then warmed to 40°C using a bead 
bath (Miris heater). Samples were sonicated with ultrasonic homogenization (Miris Ultrasonic Processor, 
1.5 s/mL) immediately prior to total macronutrient analysis. FFHM and DFHM samples were analyzed for 
total macronutrient content using mid-infrared transmission spectroscopy MIRIS HMATM (MIRIS Human 
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fat, crude protein, true protein, carbohydrate, total solid, and energy. Average macronutrient content was 
used for analysis. 
Flow Cytometry: 
Fresh FFHM and DFHM samples were spun down at 600g for 15 minutes at 4oC to obtain a cell pellet. The 
cell pellet was washed twice with flow buffer (PBS with 1% fetal calf serum and 0.002 M EDTA). Fc 
receptors were blocked with purified human IgG. Cells were labeled according to the manufacturer’s 
instructions using the following antibodies (clones) from BioLegend: CD3 (HIT3a, Pacific Blue), CD14 
(M5E2, Brilliant Violet 650) and CD16 (B73.1, FITZ); BD Bioscience: CD11b (ICRF44, APC); and 
eBioscience: CD19 (HIB19, PE) each at a 1:100 dilution. Flow cytometry was performed using a NovoCyte 
with 405, 488 and 640 nm lasers. Data was analyzed using FlowJo version 10.  
ELISA: 
Stored frozen FFHM and DFHM samples were thawed at room temperature. Samples were diluted within 
manufacturer recommended ranges as follows: IgA 1:20,000 dilution, IgG 1:1,000 dilution, Lysozyme 
1:2,000 dilution, Lactoferrin 1:200,000 dilution.  ELISA analysis was performed for each sample per 
Abcam protocol for human milk in the following manuals: IgA Human SimpleStep ELISA Kit ab196263 
(updated Oct 20, 2015), IgG Human SimpleStep ELISA Kit ab195215 (updated Aug 14, 2015), Lysozyme 
Human ELISA Kit ab108877 (updated May 18, 2016) and Human Lactoferrin SimpleStep ELISA Kit 
ab200015 (updated Aug 17, 2017). 
Bacterial Growth Inhibition: 
Fresh FFHM and DFHM samples were inoculated with Escherichia coli (E. coli, ATCC 700973) or 
Streptococcus pneumoniae (S. pneumoniae, ATCC 6303). The OD600 of the samples was approximately 
0.257, which is equivalent to a McFarland standard 1.0, as previously published.21 50 microliters of the 
bacteria were added per mL to full fat milk, defatted milk, tryptic soy broth (E. coli) or Todd Hewitt broth 
with 0.1% yeast extract (S. pneumoniae). E. coli containing samples were plated on tryptic soy agar and S. 
pneumoniae containing samples on sheep’s blood agar in serial dilutions. Negative controls of both FFHM 
and DFHM not inoculated with bacteria were plated on tryptic soy agar. Prior to plating, E. coli inoculated 
and negative control samples were incubated at 37oC with shaking at 200 RPM. S. pneumoniae samples 
were incubated at 37oC with 5% CO2 without shaking. Negative controls and bacterial samples were 
plated at 2-hour intervals from 0 to 8 hours and incubated at 37oC with 5% CO2. Bacterial colony forming 
units (CFU) were assessed 24 hours after plating to determine the effect of the different milks on bacterial 
growth. Percent growth inhibition was calculated as [(bacterial CFU in control broth – bacterial CFU in 
breastmilk)/bacterial CFU in control broth] x 100. 
Statistical Analysis: 
Parametric paired t-tests were performed on macronutrients, lactoferrin, lysozyme, sIgG and sIgA. 
Nonparametric Wilcoxon matched-pairs signed rank test was performed for all cell populations. Multiple 
paired t-tests were used for the bacterial inhibition arm of the study with statistical significance for each 
time point determined using the Holm-Sidak method. p-values of <0.05 were considered significant. For 
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Results 
DFHM contained significantly less fat and total energy than FFHM. 
Human milk defatting significantly decreases total fat and triglyceride content while leaving electrolyte 
and trace mineral content largely unchanged. 5,22 The effect of human milk defatting on other 
macronutrients, including carbohydrate and protein content, remains unknown. Mid infrared 
spectroscopy was used to compare the macronutrient content of FFHM and DFHM from the same donor, 
including total energy, fat, carbohydrate and protein content. DFHM contained significantly less total 
energy and fat than FFHM in mothers of both term and preterm infants (Figure 1A-B, p<0.01). The 
defatting process resulted in increased total carbohydrate content in both term and preterm human milk 
samples (Figure 1C, p<0.01). The total protein content of DFHM remained unchanged in preterm samples, 
with a slight decrease noted in term samples (Figure 1D, p<0.01). Overall, DFHM contained less total 
energy and fat with increased carbohydrate content compared to FFHM. 
Immune cell populations decreased during the defatting process, but other immune factors 
remained unchanged. 
Human milk contains numerous maternally derived immune cell populations, including monocytes, T 
cells, B cells, natural killer cells, neutrophils and eosinophils.13,23 These cells are thought to protect the 
mammary gland from infection, provide active immunity for the infant and guide the development of 
immunocompetence in the infant.13,23 It is unclear what effect the defatting process has on human milk 
immune cell populations. Flow cytometry was used to compare populations of total leukocytes, T cells, B 
cells, monocytes and neutrophils between FFHM and DFHM. DFHM contained significantly fewer total 
leukocytes, T cells, B cells, monocytes and neutrophils than FFHM in both term and preterm samples 
(Figure 2A-C, p<0.0001). Human milk contains many anti-microbial compounds including lactoferrin, 
lysozyme, sIgA and sIgG. Lactoferrin is one of the most abundant proteins in human milk. It binds free 
iron and makes it unavailable for bacterial growth and exerts iron-independent bactericidal activity.24 
Lysozyme is an enzyme that degrades both gram-positive and gram-negative bacterial cell walls, serving 
as a natural antibiotic.25 sIgA and sIgG pass readily through the breastmilk, providing the infant with 
protection against pathogens the mother has encountered.25 We sought to determine if the defatting 
process had an impact on anti-microbial proteins found in human milk. ELISA was used to evaluate the 
levels of lactoferrin, lysozyme, sIgA and sIgG in FFHM and DFHM. DFHM and FFHM from preterm mothers 
contained equivalent amounts of lactoferrin, while DFHM from term mothers contained slightly less 
lactoferrin than FFHM (Figure 3A, p<0.05). There was no difference in the concentrations of lysozyme, 
sIgA or sIgG between DFHM and FFHM (Figure 3B-D). Overall, DFHM contained significantly fewer 
immune cells, but equivalent anti-microbial proteins compared to FFHM except for the decrease in 
lactoferrin in term DFHM samples. 
DFHM and FFHM demonstrated equivalent bacterial growth inhibition. 
Unpasteurized FFHM contains numerous bioactive compounds that inhibit bacterial growth.21,26 To 
determine the effect of defatting human milk on bacterial growth, we inoculated FFHM and DFHM with E. 
coli or S. pneumoniae and measured bacterial growth inhibition. These bacteria were chosen because they 
are leading causes of neonatal sepsis and are some of the most likely pathogens neonates and infants 
might encounter while breastfeeding.27 FFHM and DFHM demonstrated equivalent bacterial growth 
inhibition of both E. coli and S. pneumoniae up to 8 hours after inoculation (Figure 4A-B). Although DFHM 
contained significantly fewer immune cells, it demonstrated equivalent anti-microbial activity compared 








DFHM is becoming a widely-accepted alternative to low LCT formula in the treatment of neonatal 
chylothorax, but no studies have evaluated the global macronutrient composition and immunologic 
properties of DFHM. In this study, we demonstrated that DFHM contained less total energy and fat than 
FFHM, but that carbohydrate and protein content were equal or slightly increased. DFHM contained 
significantly fewer total immune cells and immune cell subpopulations than FFHM, but the anti-microbial 
proteins lactoferrin, lysozyme, sIgA and sIgG were conserved. Most significantly, bacterial growth 
inhibition was preserved in DFHM. 
 
As expected, DFHM contained less total energy and fat than FFHM. 5-7 Consistent with a previous report, 
we found that DFHM contained an increased concentration of carbohydrates, with an average increase of 
0.2 g/100 mL compared to FFHM. 28 This increase is unlikely to be clinically relevant and is most likely 
due to a reduction in the total volume of liquid available for suspension after the defatting process, 
though this is speculation. After defatting, DFHM is deficient in not only fat, but total calories, essential 
fatty acids and fat-soluble vitamins.29 In practice, these deficiencies can be managed by supplementing 
the DFHM with low LCT formula and vitamins. 7,9 It is important to note that excessive carbohydrate 
intake increases the respiratory quotient and stimulates lipogenesis and fat deposition, which could have 
long-term consequences for infant growth and metabolism.30,31 Infants who are fed DFHM may receive a 
slightly higher concentration of carbohydrates compared to infants fed FFHM, so they should be carefully 
monitored for growth. Fortification should be tailored to each individual infant’s needs to optimize 
growth and development and to ensure they are receiving appropriate ratios of macronutrients. 
 
Total leukocytes and all immune subpopulations were significantly decreased in DFHM. This is likely due 
to the method of defatting, as it involved centrifugation followed by decanting of the non-fat containing 
milk. This decanting method left the immune cell pellet in the bottom of the centrifugation tube rather 
than in the DFHM. Although we did not evaluate for the presence of epithelial, progenitor or stem cells in 
DFHM, it is likely that they were also decreased. 23,32 FFHM is rich in leukocytes, which are believed to 
protect both the mammary gland and infant against infection while guiding development of the neonatal 
and infant immune system.13,14,33 Colostrum contains significantly more leukocytes than mature milk, but 
viable leukocytes have been recovered from the feces of infants fed mature human milk, suggesting that 
these cells remain intact and functional in the infant intestine.13 Breastmilk monocytes and macrophages 
perform phagocytosis, secrete immunoregulatory factors and release engulfed sIgA upon contact with 
bacteria in the infant intestine.13,34 Breast milk derived lymphocytes traffic from the infant’s intestine to 
the lymph nodes, spleen and liver and are thought to promote maturation of the infant’s lymphocytes.14 
All of these functions are likely important for neonatal and infant immune system maturation, and it is 
unclear if the immune cell populations remaining in DFHM are capable of performing these functions 
adequately. The presence of immune cell populations in DFHM, although reduced, are likely still superior 
to exclusive low LCT formula feeding for neonates and infants with chylothorax. Additionally, other 
methods of defatting should be investigated for effectivess of retaining the full FFHM immune cell pellet. 
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Other than a slight decrease in lactoferrin in DFHM from term lactating mothers, concentrations of 
lactoferrin, lysozyme, sIgA and sIgG were preserved after the defatting process. Previous investigators 
have reported both equivalent and different concentrations of lactoferrin in breastmilk from mothers of 
preterm and term infants during different stages of lactation.35-37 The variability of findings within the 
literature may be due to the small sample sizes and different methods used to measure lactoferrin 
levels.37 Moreover, lactoferrin in breastmilk has also been positively associated with symptoms of infant 
illness and variably affected by freezing.38-40 Concentrations of  lactoferrin range from 240-6501 µg/mL in 
mature preterm milk and from 240-4590 µg/mL in mature term milk. 24,35-37 The lactoferrin 
concentrations in our samples fell well within these published ranges (292-1595 µg/mL in preterm 
FFHM, 278-1854 µg/mL in preterm DFHM, 355-1977 µg/mL in term FFHM, 270-2111 µg/mL in term 
DFHM). Because of this, we believe the slight decrease in lactoferrin detected in the DFHM samples from 
mothers of term infants is unlikely to be clinically significant and could be the result of the confounding 
factors noted above. Importantly, DFHM and FFHM demonstrated equivalent bacterial growth inhibition 
of both the common neonatal pathogens E. coli and S. pneumoniae, suggesting that the defatting process 
does not disrupt human milk anti-microbial function.   
 
Infections caused by the loss of immunoglobulins in lymphatic fluid is a potential risk factor of congenital 
and post-surgical chylothorax.41 Human milk’s many immunologic benefits may protect infants who have 
these conditions. The human milk fat globule plays a role in the infant’s antimicrobial defense by 
releasing free fatty acids and monoglycerides via the digestive process which disrupt cell membranes of 
lipid coated micro-organisms including bacteria, viruses and protozoa.15 Our findings showed that the 
loss of milk fat in the centrifugation process did not affect the antimicrobial function of human milk 
against E.coli and S. pneumonia. However, Ogundele observed decreased bactericidal activity against a 
serum sensitive stain of E.coli in DFHM compared to FFHM.42 Further evaluation of DFHM’s antimicrobial 
function against free fatty acid and monoglyceride targeted organisms is warranted to further understand 
the effects of defatting. 
Our study has several limitations. First, not all assays were run on fresh milk. The macronutrient analysis 
and ELISA assays were run on previously frozen samples. Freezing milk has been shown to impact the 
concentrations of lactoferrin and IgA.39,40,43,44  However, a strength of the study is that each mother’s 
FFHM serves as a control. As both FFHM and DFHM samples were frozen for the same length of time, we 
expect that any protein degradation would affect these samples equally and not significantly impact our 
main findings. This study was conducted at a single center, and our patient demographic is specific to our 
institution. Therefore, the results may not be widely generalizable. Although we assessed a range of anti-
microbial proteins in this study, there are many additional immunologically important compounds 
present in human milk that were not included. These include cytokines, microRNAs, oligosaccharides and 
prebiotics, among others. 33,45,46 While the bacterial growth inhibition of E. coli and S. pneumoniae was 
preserved in DFHM, the role the human milk fat globule and other immune components play in 
supporting infant immune function needs to be investigated.  Longer term prospective studies need to be 
performed to assess the impact that defatting human milk has on the risk of other infections caused by 
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Conclusion 
While DFHM contained significantly fewer immune cells than FFHM, other anti-microbial properties were 
preserved including lactoferrin, lysozyme, sIgA, sIgG levels and bacterial growth inhibition. Based on 
these results, we recommend DFHM be used as the standard of care for neonates and infants with 
chylothorax so they can receive the known developmental and immunologic benefits of human milk. 
Special care should be taken to ensure appropriate fortification of DFHM with low LCT formula to prevent 
growth failure in this patient population.  
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